On February 10, 2026, Genprex, Inc. announced the acceptance of a patent for its Reqorsa® Gene Therapy in combination with PD-L1 antibodies for cancer treatment, with the notice issued on February 5, 2026. This patent aims to protect its clinical trial advancements and strengthen its intellectual property portfolio as it expands its reach in Australia and beyond.